Clinical trial • Phase I • Respiratory
CMR316 for Idiopathic pulmonary fibrosis
Phase I trial of CMR316 for Idiopathic pulmonary fibrosis. 112 participants.
Overview
- Trial Therapeutic Area
- Respiratory
- Trial Disease
- Idiopathic pulmonary fibrosis
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 17-01-2024
- First CTIS Authorization Date
- 09-04-2024
Trial design
Phase I trial across 1 site in Germany.
- Target Sample Size
- 112
Recruitment
- Planned Sample Size
- 112
- Recruitment Window Months
- 17
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 112
Germany
- Earliest CTIS Part Ii Submission Date
- 25-03-2024
- Latest Decision Or Authorization Date
- 22-10-2025
- Processing Time Days
- 576
- Number Of Sites
- 1
- Number Of Participants
- 112
Sites
- Site Name
- The Fraunhofer Institute For Toxicology And Experimental Medicine ITEM
- Department Name
- Division of Clinical Airway Research
- Principal Investigator Name
- Jens Hohlfeld
- Principal Investigator Email
- jens.hohlfeld@item.fraunhofer.de
- Contact Person Name
- Jens Hohlfeld
- Contact Person Email
- jens.hohlfeld@item.fraunhofer.de
Sponsor
Primary sponsor
- Full Name
- The Scripps Research Institute
- Organisation Type
- Educational Institution
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- CMR316
Related trials
Other published trials that may interest you.